Navigation Links
H3 Biomedicine and Selvita Announce Strategic Collaboration to Develop Precision Cancer Medicines
Date:9/16/2013

CAMBRIDGE, Mass. and KRAKOW, Poland, Sept. 16, 2013 /PRNewswire/ -- H3 Biomedicine Inc., a biopharmaceutical company specializing in the discovery and development of precision oncology treatments, and Selvita (PL: SLV), one of the largest drug discovery companies in Eastern Europe, announced today that they have entered into a strategic collaboration to develop breakthrough precision medicines for cancers. The companies will seek to validate the importance and druggability of several kinase targets in specific genetic contexts and to generate multiple novel drug candidates against those targets. 

(Logo: http://photos.prnewswire.com/prnh/20120430/NY96379LOGO )

Recent advances in human cancer genomics have revealed novel target opportunities that will enable new approaches to developing cancer medicines. H3 Biomedicine has built extensive and proprietary target acumen. It has also implemented a set of unique tools and research engines in the areas of cancer genomics, bioinformatics and target validation to lend biological insight to genomic findings. These capabilities will help to accelerate its collaborative drug discovery and development efforts. Selvita started its first kinase discovery programs in 2008 and, over the last five years, has built a premium scientific team with one of the world's most robust kinase discovery platforms. Together, the two companies have the know-how to leverage data from the new target opportunities revealed through cancer genomics.

"Our goal at H3 Biomedicine is to – in a very focused way – utilize the genomic information from public and proprietary data sets to identify and validate highly relevant cancer genes and to develop effective therapies against those targets," stated Markus Warmuth, M.D., President and Chief Executive Officer, H3 Biomedicine. "Both H3 Biomedicine and Selvita value early validation of drug targets to achieve preclinical proof of concept followed by translation of these findings into novel therapies for targeted patient populations. This collaboration is a key tool in our arsenal as it brings Selvita's kinase biology platform and medicinal chemistry capabilities together with H3's expertise in target validation, bioinformatics and genomics analysis. We look forward to working with Selvita to ultimately bring efficacious medicines to patients."

Pawel Przewiezlikowski, Chief Executive Officer of Selvita, said, "We are delighted to enter into this collaboration with H3 Biomedicine, and to apply our kinase discovery platform to jointly advance target discovery. The unique target identification and validation competences of H3 will bring our discovery efforts to a new level."

Krzysztof Brzozka, Chief Scientific Officer of Selvita, added "Both H3 and Selvita teams have always strived to identify novel therapeutic solutions for people living with cancer and we are very pleased that we can now join forces. This collaboration will enable us to significantly increase the breadth and depth of our pipeline."

About H3 Biomedicine Inc.
H3 Biomedicine is a biopharmaceutical company specializing in the discovery and development of oncology treatments. Using modern synthetic chemistry, chemical biology and human genetics, the company seeks to bring the next generation of cancer treatments to market with the goal of improving the lives of patients. H3 Biomedicine is based in Cambridge, Massachusetts. Visit http://www.h3biomedicine.com/ for more information.

About Selvita
Selvita is a Polish biotechnology company engaged in the discovery and development of breakthrough medicines to treat oncology, CNS and autoimmune disorders, as well as provision of drug discovery services. It was established in 2007 and currently employs 162 people, including 53 PhDs. Selvita has currently several internal projects at early or late discovery stage and is expected to move its first candidates to the clinic in 2014. The most advanced programs at Selvita are SEL24, a pre-clinical Pim kinase inhibitor, with multiple indications in hematopoietic tumors and SEL120, first-in-class small molecule inhibitor of cyclin dependent kinase CDK8. Other innovative projects currently in development include SEL141, an early stage discovery program of DYRK1A kinase inhibitors with therapeutic potential in the treatment targeting Alzheimer's disease and Down syndrome, SEL201 – novel small molecule MNK1/2 inhibitors in oncology, cancer metabolism platform and inflammasome platform.  Drug discovery clients of Selvita include more than fifty large and medium-sized pharmaceutical and biotechnology companies from USA and Europe. Selvita is listed on the NewConnect market of the Warsaw Stock Exchange in Poland (SLV). Additional information about Selvita can be found on http://www.selvita.com/

Media Contacts:

Mike Beyer
Sam Brown Inc.
(773) 463-4211
beyer@sambrown.com

Paulina Wolanin
+48 668 111 456
paulina.wolanin@selvita.com


'/>"/>
SOURCE H3 Biomedicine Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cellular Biomedicine Group Reports Second Quarter and First Half 2013 Financial Results and Business Highlights
2. Cellular Biomedicine Group Announces Expansion in the Osteoarthritis and Rheumatoid Arthritis Market
3. Cellular Biomedicine Group Announces Appointment of Corporate Controller
4. Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis
5. Cellular Biomedicine Group Provides Update and 2013 Milestones
6. Cellular Biomedicine Group Appoints Dr. Jianping Dai to the Board of Directors
7. Cellular Biomedicine Group President Presents Keynote Address at New York Stem Cell Summit
8. Cellular Biomedicine Group Announces ISO 9001:2008 Certification and ISO-14644 Cleanroom Certification
9. EastBridge Investment Group Announces Completion of its Merger with Cellular Biomedicine Group - Shareholder Conference Call to be held February 8th
10. H3 Biomedicine Expands Cambridge Facilities, Doubles Employee Base as Scientific Program Advances
11. A 300 Million Euro Boost for Biomedicine in Berlin
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... ... June 23, 2016 , ... ... launch of the Supplyframe Design Lab . Located in Pasadena, Calif., the ... future of how hardware projects are designed, built and brought to market. , ...
(Date:6/23/2016)... (PRWEB) , ... June 23, 2016 , ... In a ... Hospital in Denmark detail how a patient who developed lymphedema after being treated for ... The results could change the paradigm for dealing with this debilitating, frequent side effect ...
(Date:6/23/2016)... June 23, 2016  Blueprint Bio, a company dedicated ... the medical community, has closed its Series A funding ... . "We have received a commitment from ... we need to meet our current goals," stated ... the runway to complete validation on the current projects ...
(Date:6/23/2016)... On Wednesday, June 22, 2016, the NASDAQ Composite ... Jones Industrial Average edged 0.27% lower to finish at 17,780.83; ... has initiated coverage on the following equities: Infinity Pharmaceuticals Inc. ... NKTR ), Aralez Pharmaceuticals Inc. (NASDAQ: ARLZ ), ... more about these stocks by accessing their free trade alerts ...
Breaking Biology Technology:
(Date:5/24/2016)... IRVINE, Calif. , May 24, 2016 Ampronix facilitates superior patient care ... LMD3251MT  3D medical LCD display is the latest premium product recently added to ... ... ... Sony 3d Imaging- LCD Medical Display- Ampronix News ...
(Date:5/9/2016)... 9, 2016 Elevay is currently ... expanding freedom for high net worth professionals seeking travel ... globally connected world, there is still no substitute for ... duplicate sealing your deal with a firm handshake. This ... taking advantage of citizenship via investment programs like those ...
(Date:4/26/2016)... BANGALORE, India and LONDON ... Infosys Finacle, part of EdgeVerve Systems, a ... ), and Onegini today announced a partnership to ... banking solutions.      (Logo: http://photos.prnewswire.com/prnh/20151104/283829LOGO ... banks to provide their customers enhanced security to ...
Breaking Biology News(10 mins):